Skip to content

Posts by: Patrick Cox

Author Image for Patrick Cox

Patrick Cox

Patrick Cox brings two decades of experience in software, public policy, medical economics and biotechnology to the Agora Financial table. He is editor of the Breakthrough Technology Alert and Technology Profits Confidential, as well as a contributor to the Penny Sleuth. Cox, who spent his early childhood on the Crow Indian Reservation in Montana, studied at Boise State University and has written for USA Today, Wall Street Journal, Los Angeles Times and Reason Magazine. Cox has also been featured in The Baltimore Sun and CNBC Business Magazine.

  1. Daily Reckoning

    Banking on Your Phone • February 3, 2012

    America has lagged behind much of the world in terms of digital wallets. Elsewhere, people routinely use phones instead of credit cards. There are several reasons for this. Partly, it is because North America saw mobile phones so early. When other regions finally rolled out mobile phones, infrastructures were more modern. The larger reason, however, …Read more…

  2. Breakthrough Technology Alert

    Blockbuster Anatabloc Data Released • January 31, 2012

    There’s great news from Star Scientific, with the first of clinical data showing that Anatabloc works as well in human studies as it does in animal studies. And that’s just the beginning……Read more…

  3. Penny Sleuth

    Invest In This Emerging Multibillion-Dollar Market • January 24, 2012

    The business of medical biotechnologies operates within an extraordinarily complex regulatory system. The SEC and the IRS are only the beginning of the story… In the United States, the Food and Drug Administration determines what can legally be sold. It even exercises control over what can be said by companies about medical therapies. Elsewhere, other …Read more…

  4. Penny Sleuth

    Inside the Consumer Electronics Show: The Hottest in 3D and OLED Technology • January 19, 2012

    My colleague Ray Blanco and I are back from the Consumer Electronics Show (CES) in Las Vegas. The big story this year was the convergence in consumer electronics. Specifically, it was the arrival of extraordinary high-definition 3-D as well as “smart” TVs. In fact, Ray and I had backstage passes for the biggest 3-D events. …Read more…

  5. Breakthrough Technology Alert

    Explosive Opportunity From This Emerging Multibillion-Dollar Nutraceutical Market • January 17, 2012

    From creatine and xylitol to Star Scientific’s truly historic anti-inflammation breakthrough, anatabine, nutraceutical legitimacy has risen dramatically. Bioinformatics, molecular biology and nutrigenomics are contributing to this new field outside the bureaucratic hand of the regulators – with all the opportunities and risks that it implies. This month, I’d like to tell you about the company that is best positioned to profit from this disruptive revolution… …Read more…

  6. Breakthrough Technology Alert

    Arrowhead and Alnylam Collaborate and BioMimetic Forced Into Euro Play • January 10, 2012

    As you know, Big Pharma has a habit of diving headfirst into brand-new scientific areas when they first appear. Then, when traders lose patience with long-term road maps, they divest. In the incredibly promising field of RNA interference, Alnylam was the single biggest recipient of Big Pharma enthusiasm, with major funding from Merck in 2003. Later, a collaboration with Roche was initiated. …Read more…

  7. Penny Sleuth

    Mass Marketing Regenerative Medicine: A Small-Cap Biotech Set for Explosive Gains • January 6, 2012

    Don’t be discouraged by the “down market.” Many investors are depressed or fearful today because share prices been beaten down across the board. Those investors don’t understand business cycles and the way to play them. Traders obsessed with short-term results have never been as successful as patient long-term investors. Get-rich-quick investment advice is a fantasy. …Read more…